Resona Asset Management Co. Ltd. Has $53.85 Million Holdings in Zoetis Inc. $ZTS

Resona Asset Management Co. Ltd. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 427,933 shares of the company’s stock after acquiring an additional 7,464 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Zoetis were worth $53,851,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. RFG Advisory LLC grew its position in Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership grew its position in Zoetis by 3.5% in the 4th quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares in the last quarter. Evergreen Capital Management LLC grew its position in Zoetis by 3.3% in the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after purchasing an additional 85 shares in the last quarter. Beese Fulmer Investment Management Inc. grew its position in Zoetis by 2.4% in the 3rd quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. grew its position in Zoetis by 4.7% in the 4th quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock worth $240,000 after purchasing an additional 86 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 4.8%

Zoetis stock opened at $77.78 on Tuesday. Zoetis Inc. has a twelve month low of $72.38 and a twelve month high of $172.23. The firm has a 50 day moving average price of $111.39 and a 200-day moving average price of $120.28. The company has a market capitalization of $32.61 billion, a P/E ratio of 12.90, a P/E/G ratio of 1.21 and a beta of 0.87. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the company earned $1.48 earnings per share. The firm’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts predict that Zoetis Inc. will post 6.91 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. UBS Group reduced their price objective on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Citigroup reduced their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday. Stifel Nicolaus set a $105.00 price objective on shares of Zoetis in a research report on Friday, May 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a research report on Friday. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $134.75.

Insider Activity

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Frank A. Damelio acquired 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 11,650 shares of company stock valued at $886,384 in the last three months. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.